Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

177-Lu TE 1132

Next Previous
Drug Profile

177-Lu TE 1132

Alternative Names: 177Lu-TE-1132; TE-1132

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunwork
  • Class Antineoplastics; Drug conjugates; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action CA-19-9 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jul 2025 T-E Meds plans a GLP toxicology and safety study of 177Lu TE 1132 in the first half of 2027 (T-E Meds pipeline, July 2025)
  • 10 Jan 2023 177-Lu TE 1132 is available for licensing as of 05 Jan 2023. https://www.immunwork.com/eforms.php?lang=en&tb=1
  • 05 Jan 2023 Preclinical trials in Cancer in Taiwan (Parenteral) before January 2023 (Immunwork pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top